Daily Cardiology Research Analysis
Analyzed 76 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology studies stood out: a multicenter randomized trial showed digoxin reduces death or worsening heart failure in symptomatic rheumatic heart disease; a rigorous JAMA meta-analysis found digitalis glycosides reduce worsening heart failure events without mortality benefit in HFmrEF/HFrEF; and a large single-cell/spatial atlas uncovered an ENO1-driven glycolytic–immune axis driving aortic dissection, revealing therapeutic targets.
Research Themes
- Reappraisal of digitalis therapy in contemporary heart failure
- Metabolic–immune mechanisms in vascular disease (aortic dissection)
- Evidence synthesis guiding adjunctive therapy and risk reduction
Selected Articles
1. Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial.
In 1,759 symptomatic rheumatic heart disease patients, daily digoxin reduced the composite of all-cause death or new/worsening heart failure over a median 2.1 years (HR 0.82) mainly via fewer worsening HF events, without affecting all-cause mortality and with low toxicity-related discontinuation.
Impact: This large randomized, placebo-controlled trial fills a critical evidence gap for digoxin in rheumatic heart disease and demonstrates event reduction with acceptable safety.
Clinical Implications: Digoxin can be considered as adjunct therapy to reduce worsening HF events in symptomatic rheumatic heart disease, particularly in patients with atrial fibrillation, with careful dosing and monitoring.
Key Findings
- Primary composite (all-cause death or new/worsening HF) reduced with digoxin vs placebo: HR 0.82 (95% CI 0.70-0.97; P=0.02).
- New-onset or worsening HF reduced: HR 0.82 (95% CI 0.69-0.98); most managed without hospitalization.
- All-cause mortality unchanged: HR 0.94 (95% CI 0.70-1.26).
- Low discontinuation due to suspected toxicity: 1.1% vs 0.1% (placebo).
Methodological Strengths
- Multicenter randomized, placebo-controlled design with stratification by baseline rhythm.
- Adequate sample size with adjudicated outcomes and prespecified endpoints; trial registration.
Limitations
- Conducted in Indian tertiary centers with predominant mitral stenosis; generalizability to non-RHD or other settings may be limited.
- Not powered to detect mortality differences; serum digoxin levels and dose–response not detailed.
Future Directions: Evaluate dose optimization, therapeutic drug monitoring strategies, and applicability across diverse RHD phenotypes and resource settings; assess long-term mortality and quality-of-life effects.
IMPORTANCE: Heart failure is the most common cause of death in patients with rheumatic heart disease. The efficacy and safety of digoxin in this population are not known. OBJECTIVE: To determine if digoxin, compared with placebo, improves the composite of death or new-onset or worsening heart failure in patients with symptomatic rheumatic heart disease. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, placebo-controlled trial enrolling patients with rheumatic heart disease who additionally had heart failure or atrial fibrillation or were already taking digoxin at 12 tertiary care hospitals in India between February 25, 2022, and August 31, 2024; median follow-up was 2.1 years (until December 15, 2025). INTERVENTIONS: Patients were randomized in a 1:1 ratio, stratified by baseline rhythm, to receive oral digoxin, 0.125 to 0.25 mg once daily (n = 885), or matching placebo (n = 884). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause death or new-onset or worsening heart failure within 36 months of follow-up or until study end, whichever occurred first. Key secondary outcomes were all-cause death, new-onset or worsening heart failure, and a composite of heart failure-related death or new-onset or worsening heart failure. RESULTS: Of 1769 enrolled patients, 1759 took at least 1 dose of the study medication and were included in the primary analysis. The mean age was 46 years and 72% were female. Most patients (81.5%) had mixed lesions involving multiple valves, with 85% having moderate to severe mitral stenosis. Atrial fibrillation was present in 70%, and 90% were in New York Heart Association class II to IV. The primary composite outcome occurred in 276 patients (31.4%) receiving digoxin and 312 (35.5%) receiving placebo (hazard ratio, 0.82; 95% CI, 0.70-0.97; P = .02). New-onset or worsening heart failure occurred in 227 patients (25.8%) receiving digoxin and in 257 (29.2%) receiving placebo (hazard ratio, 0.82; 95% CI, 0.69-0.98). Most episodes of worsening heart failure were treated with augmentation of oral or intravenous diuretics without hospitalization. Death from any cause occurred in 88 patients (10%) receiving digoxin and 91 (10.4%) receiving placebo (hazard ratio, 0.94; 95% CI, 0.70-1.26). Ten patients receiving digoxin (1.1%) and 1 receiving placebo permanently discontinued study medication due to suspected digoxin toxicity. CONCLUSIONS AND RELEVANCE: In patients with symptomatic rheumatic heart disease, digoxin reduced the risk of a composite of all-cause death or new-onset or worsening heart failure, with little risk of toxicity. TRIAL REGISTRATION: CTRI Identifier: CTRI/2021/04/032858.
2. Integrated Single-Cell and Spatial Analysis Reveals a Metabolic-Immune Axis Driving Aortic Dissection.
A multi-cohort single-cell and spatial atlas (767,018 cells from 110 aortic samples) identified loss of an elastin-rich FBN1+ fibroblast subset and ENO1-driven glycolytic reprogramming of vSMCs that secrete MIF to recruit/pro-inflammatory polarize macrophages, culminating in proteolysis and matrix degradation; ENO1 knockdown attenuated vSMC switching, macrophage inflammation, and aortic dissection progression.
Impact: This study provides a mechanistic, multi-system map linking stromal cell loss and vSMC metabolic reprogramming to immune activation and matrix destruction in human aortic dissection, revealing actionable targets (e.g., ENO1, MIF axis).
Clinical Implications: Suggests therapeutic strategies targeting vSMC glycolysis (ENO1) or MIF–macrophage signaling to stabilize the aortic wall; identifies cell-state biomarkers (FBN1+ fibroblasts) potentially useful for risk stratification.
Key Findings
- Elastin-rich FBN1+/MFAP5+/LOX+ fibroblast subset declines with age and is markedly depleted in aortic dissection, linking fibroblast loss to wall vulnerability.
- vSMCs undergo ENO1-driven glycolytic reprogramming under hypoxia, losing contractility and adopting a synthetic MIF-secreting phenotype.
- MIF–macrophage receptor interactions promote macrophage recruitment and pro-inflammatory polarization, upregulating proteolytic/fibrinolytic pathways and accelerating ECM degradation.
- ENO1 knockdown (in vitro and in vivo) inhibits vSMC switching, reduces macrophage inflammation, and slows aortic dissection progression.
Methodological Strengths
- Integration of single-cell and spatial transcriptomics across 110 samples with 767,018 high-quality cells.
- Mechanistic validation with in vitro and in vivo ENO1 knockdown experiments linking pathway to disease modulation.
Limitations
- Observational omics data cannot fully establish causality across all inferred interactions.
- Human tissue heterogeneity and species differences may limit translation; therapeutic targeting requires safety/efficacy studies.
Future Directions: Preclinical testing of ENO1 inhibitors or metabolic modulators and MIF–receptor blockade; development of biomarkers (e.g., FBN1+ fibroblast signals) for patient stratification and monitoring.
Although single-cell studies have profiled diseased aorta, mechanisms driving aortic dissection (AD) remain largely elusive owing to limited cohorts. Here, we integrate single-cell and spatial transcriptomic data from 110 thoracic aortic samples (80 individuals; control, aneurysm, dissection; 767 018 high-quality cells) to generate a comprehensive thoracic-aorta cellular-molecular atlas. We identify an elastin-rich fibroblast subset (Fibro_C1_FBN1+; FBN1, MFAP5, LOX) that declines with age and is markedly depleted in AD, linking fibroblast loss to increased aortic wall vulnerability and dissection risk. Vascular smooth muscle cells (vSMCs) undergo ENO1-driven glycolytic reprogramming under hypoxia, lose contractility and adopt a synthetic, MIF-secreting phenotype that engages macrophage receptors to promote macrophage recruitment and pro-inflammatory polarization, leading aggregated macrophages to upregulate proteolytic and fibrinolytic pathways and thereby accelerate extracellular-matrix degradation. In vitro and in vivo, ENO1 knockdown inhibits vSMC switching, reduces macrophage inflammation, and slows AD progression. This stromal-immune axis suggests potential therapeutic targets in AD.
3. Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis.
Across 3 large placebo-controlled RCTs (n=9,013), digitalis glycosides reduced the composite of cardiovascular death or first worsening heart failure (HR 0.85), driven by fewer worsening HF events (HR 0.75), without effects on cardiovascular or all-cause mortality.
Impact: Provides contemporary, high-level synthesis supporting digitalis glycosides as add-on therapy to reduce worsening HF events in HFmrEF/HFrEF, informing guideline and practice discussions.
Clinical Implications: Consider digitalis as an adjunct to reduce HF worsening in HFmrEF/HFrEF when symptoms persist despite guideline-directed therapy, with toxicity monitoring and individualized patient selection.
Key Findings
- Composite cardiovascular death or first worsening HF reduced: HR 0.85 (95% CI 0.80-0.90; P<.001).
- First worsening HF event reduced: HR 0.75 (95% CI 0.69-0.81; P<.001).
- No effect on cardiovascular death (HR 0.99) or all-cause death (HR 0.97).
- No significant heterogeneity by trial, digitalis type, or background HF therapy.
Methodological Strengths
- PRISMA-compliant meta-analysis restricted to large placebo-controlled RCTs.
- Rigorous bias assessment (RoB2) and consistent findings across trials.
Limitations
- Fixed-effects modeling may underrepresent between-trial heterogeneity; individual patient data not available.
- Trials largely predate contemporary quadruple therapy; applicability alongside modern regimens requires careful consideration.
Future Directions: Prospective pragmatic trials assessing digitalis on top of contemporary HF therapy, dose–response and therapeutic monitoring strategies, and subgroup analyses (e.g., AF status, sex, CKD).
IMPORTANCE: Digitalis glycosides may be used as additional therapy in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or HF with reduced EF (HFrEF). OBJECTIVE: To assess the effect of digitalis glycosides on clinical outcomes in patients with HFmrEF or HFrEF. DATA SOURCES AND STUDY SELECTION: PubMed was searched from inception to March 1, 2026, using medical subject headings and keywords related to digitalis glycosides and HF. The review was restricted to placebo-controlled randomized clinical trials including more than 1000 patients and articles published in the English language. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 reviewers who followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline. Risk of bias was assessed with the Cochrane Risk of Bias tool (version 2). A fixed-effects model was used to estimate the hazard ratios (HRs) with 95% CIs. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of time to cardiovascular death or first worsening HF event. Secondary outcomes included individual components of the composite outcome and time to all-cause death. RESULTS: A total of 3 studies met the inclusion criteria and included 9013 patients with HFmrEF or HFrEF (weighted mean age, 64.5 [weighted SD, 11.2] years; 22% female and 78% male). The composite outcome of cardiovascular death or first worsening HF event occurred in 1852 of 4510 patients (41%) in the digitalis glycoside group vs 2037 of 4503 patients (45%) in the placebo group (HR, 0.85 [95% CI, 0.80-0.90]; P < .001). First worsening HF event occurred in 1183 (26%) patients in the digitalis glycoside group vs 1474 (33%) patients in the placebo group (HR, 0.75 [95% CI, 0.69-0.81]; P < .001). There were 1224 cardiovascular events in the digitalis glycoside group vs 1224 in the placebo group (27% of participants in each group; HR, 0.99 [95% CI, 0.92-1.07]; P = .81) and there were 1466 vs 1497, respectively, all-cause deaths (32% of participants vs 33%; HR, 0.97 [95% CI, 0.90-1.04]; P = .41). There was no statistically significant heterogeneity by trial, type of digitalis glycoside treatment, or extent of background HF therapy. CONCLUSIONS AND RELEVANCE: Treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening HF event in patients with HFmrEF or HFrEF, mainly through a lower risk of worsening HF events. There was no statistically significant interaction with important study characteristics, including the extent of HF background therapy or type of digitalis glycosides treatment. These results suggest digitalis glycosides may be used as additional medical therapy to reduce worsening HF events in patients with HFmrEF or HFrEF.